A recombinant subunit based Zika virus vaccine is efficacious in nonhuman primates

Liana O. Medina, Albert To, Michael M. Lieberman, Teri Ann S. Wong, Madhuri Namekar, Eileen Nakano, Hanne Andersen, Jake Yalley-Ogunro, Jack Greenhouse, Stephen Higgs, Yan Jang S. Huang, Dana L. Vanlandingham, Jaime S. Horton, David E. Clements, Axel T. Lehrer

Research output: Contribution to journalArticle

11 Scopus citations

Abstract

Zika Virus (ZIKV), a virus with no severe clinical symptoms or sequelae previously associated with human infection, became a public health threat following an epidemic in French Polynesia 2013-2014 that resulted in neurological complications associated with infection. Although no treatment currently exists, several vaccines using different platforms are in clinical development. These include nucleic acid vaccines based on the prM-E protein from the virus and purified formalin-inactivated ZIKV vaccines (ZPIV) which are in Phase 1/2 clinical trials. Using a recombinant subunit platform consisting of antigens produced in Drosophila melanogaster S2 cells, we have previously shown seroconversion and protection against viremia in an immunocompetent mouse model. Here we demonstrate the efficacy of our recombinant subunits in a non-human primate (NHP) viremia model. High neutralizing antibody titers were seen in all protected macaques and passive transfer demonstrated that plasma from these NHPs was sufficient to protect against viremia in mice subsequently infected with ZIKV. Taken together our data demonstrate the immunogenicity and protective efficacy of the recombinant subunit vaccine candidate in NHPs as well as highlight the importance of neutralizing antibodies in protection against ZIKV infection and their potential implication as a correlate of protection.

Original languageEnglish (US)
Article number2464
JournalFrontiers in immunology
Volume9
Issue numberNOV
DOIs
StatePublished - Nov 8 2018
Externally publishedYes

Keywords

  • CoVaccine HT™
  • Cynomolgus macaque
  • Microsphere immunoassay (MIA)
  • Recombinant subunit
  • Vaccine
  • Zika virus (ZIKV)

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'A recombinant subunit based Zika virus vaccine is efficacious in nonhuman primates'. Together they form a unique fingerprint.

  • Cite this

    Medina, L. O., To, A., Lieberman, M. M., Wong, T. A. S., Namekar, M., Nakano, E., Andersen, H., Yalley-Ogunro, J., Greenhouse, J., Higgs, S., Huang, Y. J. S., Vanlandingham, D. L., Horton, J. S., Clements, D. E., & Lehrer, A. T. (2018). A recombinant subunit based Zika virus vaccine is efficacious in nonhuman primates. Frontiers in immunology, 9(NOV), [2464]. https://doi.org/10.3389/fimmu.2018.02464